奧托立夫 ALV 深 滬
等待開盤 09-19 09:30:00 美东时间
126.73
+1.800
+1.44%
華盛通- 最 高126.82
- 今 開124.82
- 成交量 38.93万股
- 最 低 124.255
- 昨 收 124.93
- 總市值 97.34亿
- 52周最高 127.89
- 市盈率 靜 15.77
- 換手率 0.00%
- 52周最低 73.94
- 委 比 52.38%
- 總股本 7680.72万
- 歷史最高 127.89
- 量 比 0.83
- 振 幅 2.05%
- 歷史最低 -22.69
- 每 手 1
- 風險率 10.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alvopetro Declares Q3 2025 Dividend, Reinforcing Growth and Shareholder Returns
Alvopetro Energy ( ($TSE:ALV) ) has shared an update. Alvopetro Energy Ltd. has...
09-16 06:09
Autoliv Approves Retention Award for Magnus Jarlegren
Autoliv ( ($ALV) ) just unveiled an announcement. On September 8, 2025, Autoliv...
09-11 22:29
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Autoliv Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Autoliv (NYSE:ALV) underwent analysis by 7 analysts in the last quarter, reveal...
09-09 21:01
Wells Fargo Maintains Equal-Weight on Autoliv, Raises Price Target to $126
Wells Fargo analyst Colin Langan maintains Autoliv (NYSE:ALV) with a Equal-Weight and raises the price target from $106 to $126.
09-09 20:58
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Alvotech announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, September 8-10, 2025. Dr. Balaji Prasad, Chief Strategy Officer, will join a fireside chat on September 10 at 10:45 am EDT. The event will be live-streamed and available for replay for 90 days. Alvotech focuses on developing and manufacturing biosimilar medicines, has launched two biosimilars, and collaborates with global partners to e...
09-04 13:15
合肥今年新能源汽车产量已超百万辆
近日从合肥市工信局获悉，全市2024年新能源汽车实际产量截至10月21日已超100万辆，远超去年全年74.6万辆的总产量。预计，2024年合肥全年新能源汽车产量...
08-24 08:32
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Alvotech and Advanz Pharma announced the European Commission's approval of Mynzepli® (aflibercept), a biosimilar to Eylea®, for treating conditions like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusions. Approved across all European Economic Area countries, Mynzepli® is available as a pre-filled syringe and vial. The approval follows a confirmatory clinical study demonstrating therapeutic equivalence ...
08-21 08:30
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Alvotech, a global biotech company, announced the appointment of Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. With over 25 years of experience in the life-science industry, Ling joins Alvotech from DNB Carnegie, where he served as a Senior Equity Analyst covering life-science companies. His background spans marketing, sales, and financial roles, including portfolio management and equity analysis. Alvotech’s chairman an...
08-20 10:05
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Alvotech will release its first-half 2025 financial results after U.S. markets close on August 13, 2025, and hold a conference call on August 14, 2025, at 8:00 am EDT to discuss the results and recent business highlights. The webcast will be available on Alvotech’s investor portal and archived for 90 days. Alvotech, a global biosimilar developer and manufacturer, has two approved biosimilars and nine candidates in its pipeline targeting various t...
08-06 12:00
